Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDA User Fee Negotiations Finished; Backlog To Be Mostly Cleared By Year Five

Executive Summary

The finalized generic drug user fee agreement would clear most of the ANDA application backlog by the end of the first program cycle.

You may also be interested in...



GDUFA Stakeholder Deadline May Come After Negotiations Conclude

Generic drug user fee reauthorization talks remain on schedule and are expected to last about four months.

GDUFA Stakeholder Deadline Extended; Are Talks Delayed?

FDA says stakeholders who want to participate in monthly updates during formal generic drug user fee talks have until late April 2016 to give notice, prompting questions about the negotiation schedule.

Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree

Small business owners say the GDUFA facility and other fees are too expensive, especially while waiting for ANDAs to be approved, but any small business waiver is unlikely until GDUFA II.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053751

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel